Lantern Pharma (NASDAQ: LTRN) announced the expansion of its predictBBB™ platform into a Large Quantitative Model (LQM), delivering a real-time, web-based molecular intelligence engine that enables researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. The enhanced platform leverages Lantern’s RADR® AI technology to provide rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture and topological mapping, with benchmark-validated performance and accessibility designed to streamline drug discovery workflows and broaden access to advanced computational tools.
This expansion marks a significant step in Lantern’s mission to transform drug development through artificial intelligence and machine learning. The predictBBB platform, originally developed to predict blood-brain barrier permeability, has now evolved into a robust tool that can assess multiple aspects of a molecule’s developability simultaneously. By integrating RADR’s AI capabilities, the platform can process complex molecular data and deliver insights that were previously time-consuming and resource-intensive to obtain. Researchers can now input a simplified molecular-input line-entry system (SMILES) notation and receive a detailed profile that includes physicochemical properties, drug-likeness scores, structural architecture analysis, and topological mapping.
The implications of this announcement are far-reaching for the pharmaceutical and biotechnology industries. Traditional drug discovery involves lengthy and costly processes to evaluate potential candidates, with many molecules failing due to poor developability characteristics. Lantern’s LQM aims to accelerate this early-stage screening by providing rapid, comprehensive assessments that can help researchers prioritize the most promising compounds. This could lead to reduced development times and lower costs, ultimately bringing new therapies to patients faster. The platform’s web-based accessibility also democratizes access to advanced computational tools, allowing smaller research teams and academic institutions to leverage AI-driven insights without requiring extensive in-house computational infrastructure.
Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage precision oncology company that leverages AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
Additionally, Lantern’s withZeta.ai multi-agentic AI co-scientist platform is now commercially available as a subscription-based research platform, representing a new revenue stream for the company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. For more information, visit the company’s newsroom at https://ibn.fm/LTRN.
The full press release can be viewed at https://ibn.fm/XqWld.
